Researchers discovered that PARP inhibitors in ovarian cancer and breast cancer can cause PD-L1 overexpression, which is a biomarker for the success of anti-PD1 or anti-PD-L1 combo treatment [10, 15]. This evidence concerns the gene PDCD1 and breast cancer.